10x Genomics (TXG) Receivables - Other (2024 - 2026)

10x Genomics (TXG) has 3 years of Receivables - Other data on file, last reported at -$18.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other changed N/A year-over-year to -$18.1 million; the trailing twelve-month figure through Mar 2026 stood at -$18.2 million (changed N/A YoY), and the FY2025 full-year result was $35.5 million, up 5754.79% from the prior year.
• Receivables - Other retreated to -$18.1 million in Q1 2026, from $35.5 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $69.1 million in Q2 2025 to a low of -$18.1 million in Q1 2026.
• A 3-year average of $27.8 million and a median of $35.5 million in 2025 frame the typical range for Receivables - Other.
• Peak annual rise in Receivables - Other reached 51877.45% in 2025, while the deepest fall reached 51877.45% in 2025.
• Tracing TXG's Receivables - Other over 3 years: stood at -$102000.0 in 2024, then jumped by 34884.31% to $35.5 million in 2025, then plunged by 151.1% to -$18.1 million in 2026.
• Business Quant data shows TXG's Receivables - Other at -$18.1 million in Q1 2026, $35.5 million in Q4 2025, and $52.8 million in Q3 2025.